Serotonin-mediated thrombosis and selective serotonin re-uptake inhibition

Philip R. Belcher

doi:10.1160/TH09-07-0437

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(03): 424-425
DOI: 10.1160/TH09-07-0437

Editorial Focus

Schattauer GmbH

Serotonin-mediated thrombosis and selective serotonin re-uptake inhibition

Philip R. Belcher

¹University of Glasgow, Cardiovascular Science, Glasgow, Scotland, UK

› Author Affiliations

Abstract

Full Text

References

References
1 de Clerck FF, Janssen PA. Amplification mechanisms in platelet activation and arterial thrombosis. J Hypertens Suppl 1990; 08: S87-93.
2 de Clerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991; 17 (Suppl. 05) S1-5.
3 Galan AM, Lopez-Vilchez I, Diaz-Ricart M. et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102: 511-519.
4 Belcher P, Drake-Holland AJ, Hynd J. et al. Dispersion of coronary artery thrombi by antagonism of platelet serotonin2 receptor in the dog. Cardiovasc Res 1992; 26: 292-296.
5 Belcher P, Drake-Holland AJ, Noble MI. Antagonism of the platelet 5HT2 receptor in the presence of thrombolysis. Int J Cardiol 1994; 43: 11-20.
6 Menys VC. Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro. Cardiovasc Res 1993; 27: 1916-1919.
7 Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81.
8 Duerschmied D, Canault M, Lievens D. et al. Serotonin stimulated platelet receptor shedding by tumor necrosis factor-alpha-converting enzyme (ADAM17). J Thromb Haemost 2009; 07: 1163-1171.
9 Frankhauser P, Baranyai R, Ahrens T. et al. Platelet surface P-selectin expression is highly correlated with serotonin transporter density in human subjects. Thromb Haemost 2008; 100: 1201-1203.
10 Carneiro AMD, Cook EH, Murphy DL. et al. Interactions between integrin aIIbb3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008; 118: 1544-1552.
11 Günther L, Liebscher S, Jähkel M. et al. Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group and isolation-housed mice. Eur J Pharmacol 2008; 593: 49-61.
12 Pandey GN, Pandey SC, Dwivedi Y. et al. Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior. Am J Psychiatry 1995; 152: 850-855.
13 Roth BL, Willins DL, Kristansen K. et al. 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 1998; 79: 231-257.
14 Klimek V, Zak-Knapik J, Mackowiak M. Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J Psychiatry Neurosci 1994; 19: 63-67.
15 Bakish D, Cavazzoni P, Chudzik J. et al. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997; 41: 184-190.
16 Yamauchi M, Miyara T, Matsushima T. et al. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 2006; 1067: 164-169.
17 Menys VC, Smith CC, Lewins P. et al. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci 1996; 91: 87-92.